前收市價 | 0.0400 |
開市 | 0.0400 |
買盤 | 0.0000 |
賣出價 | 0.7500 |
拍板 | 6.00 |
到期日 | 2024-05-17 |
今日波幅 | 0.0400 - 0.0400 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 57 |
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.